We are pleased to announce our latest news to you.

We are delighted to share with you that the European Alliance for Newborn Screening in SMA received the 2022 EURORDIS Company Award for Patient Engagement as part of the Black Pearl Awards.

We are proud to be the Secretariat of the European Alliance for SMA Newborn Screening

Hopefully you share our perspective that patient engagement should be fully integrated into drug development. If you know anyone that needs convincing that effective patient engagement in the industry matters, here is our list

Patient preferences are used by Industry, Regulators, HTA/payers, academics, physicians, patients to inform decision making regarding topics like benefit/risk assessment, labeling, early access, and relevant endpoints

patient2site: Technology combined with unmatched patient engagement services to create successful patient recruitment strategies, trial awareness and boost enrollment.

Patient Partnering in Clinical Development (PPCD) 2021 is focusing on how this influences the patient’s journey and involvement as partners and what we have learnt to put in place for the next steps to the new norm!

In a number of projects admedicum and Justin Stindt Consulting have already successfully merged their expertise. The companies now are combining their skills tighter to create value for both patients and industry.

Following continuous growth and internationalisation of collaboration with patients and companies across Europe we are excited to announce the opening of admedicum Paris, France.

It’s time for Europe to bridge the gap in newborn screening for spinal muscular atrophy. The European Alliance for Newborn Screening in Spinal Muscular Atrophy calls upon the government of Europe to include a test for SMA in national newborn screening programmes.

Search the news